1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Exeliom Biosciences

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2016

Location

Paris France

Primary Industry

Biotechnology

About

Founded in 2016 and based in Dijon, France, Nextbiotix, SAS operates as a biotechnology company using commensal bacteria as drugs to treat major inflammatory bowel diseases.
Current Investors
Auriga Partners, Sofimac Innovation, Capital Grand Est

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.exeliombio.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.